Dr. Ramalingam on Treatment Parameters for Osimertinib in Lung Cancer

Suresh S. Ramalingam, MD, FASCO
Published: Sunday, Feb 09, 2020



Suresh S. Ramalingam, MD, FASCO, deputy director of Winship Cancer Institute of Emory University, discusses the current treatment parameters for osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

Patients diagnosed with lung adenocarcinoma or nonsquamous lung cancer receive molecular testing, and treatment should be held until the results are given, explains Ramalingam. For patients with EGFR exon 19 or exon 21 mutations, the frontline therapy is osimertinib outside of a clinical trial.

An ECOG trial examining osimertinib plus bevacizumab (Avastin) versus osimertinib alone will soon launch and give insight on combining another targeted agent with the best-in-class TKI inhibitor, says Ramalingam. Research is also looking into understanding the mechanisms of resistance to osimertinib and developing novel approaches to delay or overcome resistance, concludes Ramalingam.

<<< View more from the 2020 Winter Lung Cancer Conference


Suresh S. Ramalingam, MD, FASCO, deputy director of Winship Cancer Institute of Emory University, discusses the current treatment parameters for osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

Patients diagnosed with lung adenocarcinoma or nonsquamous lung cancer receive molecular testing, and treatment should be held until the results are given, explains Ramalingam. For patients with EGFR exon 19 or exon 21 mutations, the frontline therapy is osimertinib outside of a clinical trial.

An ECOG trial examining osimertinib plus bevacizumab (Avastin) versus osimertinib alone will soon launch and give insight on combining another targeted agent with the best-in-class TKI inhibitor, says Ramalingam. Research is also looking into understanding the mechanisms of resistance to osimertinib and developing novel approaches to delay or overcome resistance, concludes Ramalingam.

<<< View more from the 2020 Winter Lung Cancer Conference



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x